1. |
付艳, 邢卉春. 原发性肝癌的流行状况及危险因素分析. 中国肝脏病杂志(电子版), 2014, 6(2): 87-90.0.
|
2. |
陈琳, 张志伟, 陈义发, 等. 293 例原发性肝癌术后复发的综合治疗效果分析. 腹部外科, 2017, 30(2): 89-92, 96.0.
|
3. |
Hockel M, Schlenger K, Aral B, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res, 1996, 56(19): 4509-4515.
|
4. |
郑怀, 石学林, 黄广升. HIF-1α、ToPo-Ⅱ、Ki-67 在乳腺癌组织中的表达研究. 白求恩医学杂志, 2016, 14(2): 139-141.0.
|
5. |
Sundfør K, Lyng H, Rofstad EK. Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. Br J Cancer, 1998, 78(6): 822-827.
|
6. |
Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res, 1996, 56(5): 941-943.
|
7. |
Ogiso Y, Tomida A, Lei S, et al. Proteasome inhibition circumvents solid tumor resistance to topoisomeraseⅡ-directed drugs. Cancer Res, 2000, 60(9): 2429-2434.
|
8. |
Beavon IR. Regulation of E-cadherin: does hypoxia initiate the metastatic cascade? Mol Pathol, 1999, 52(4): 179-188.
|
9. |
Dachs GU, Tozer GM. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer, 2000, 36(13 Spec No): 1649-1660.
|
10. |
Jögi A, Øra I, Nilsson H, et al. Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc Natl Acad Sci U S A, 2002, 99(10): 7021-7026.
|
11. |
黄耿文, 杨连粤. 缺氧致肿瘤恶性转化的分子机制. 世界华人消化杂志, 2001, 9(11): 1300-1304.0.
|
12. |
Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol, 1992, 12(12): 5447-5454.
|
13. |
Schmaltz C, Hardenbergh PH, Wells A, et al. Regulation of proliferation-survival decisions during tumor cell hypoxia. Mol Cell Biol, 1998, 18(5): 2845-2854.
|
14. |
Zhao B, Ma A, Cai J, et al. VEGF-A regulates the expression of VEGF-C in human retinal pigment epithelial cells. Br J Ophthalmol, 2006, 90(8): 1052-1059.
|
15. |
Neagoe PE, Lemieux C, Sirois MG. Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer. J Biol Chem, 2005, 280(11): 9904-9912.
|
16. |
Veikkola T, Karkkainen M, Claesson-Welsh L, et al. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res, 2000, 60(2): 203-212.
|
17. |
Inda AM, Andrini LB, García MN, et al. Evaluation of angiogenesis with the expression of VEGF and CD34 in human non-small cell lung cancer. J Exp Clin Cancer Res, 2007, 26(3): 375-378.
|
18. |
Clauss M, Schaper W. Vascular endothelial growth factor: a jack-of-all-trades or a nonspecific stress gene? Circ Res, 2000, 86(3): 251-252.
|
19. |
Jacquemier J, Mathoulin-Portier MP, Valtola R, et al. Prognosis of breast-carcinoma lymphagenesis evaluated by immunohistochemical investigation of vascular-endothelial-growth-factor receptor 3. Int J Cancer, 2000, 89(1): 69-73.
|
20. |
Rak J, Mitsuhashi Y, Sheehan C, et al. Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res, 2000, 60(2): 490-498.
|
21. |
Van Valckenborgh E, Croucher PI, De Raeve H, et al. Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model. Am J Pathol, 2004, 165(3): 869-878.
|
22. |
颜子颖, 王海林. 精编分子生物学实验指南. 北京: 科学出版社, 1998: 286-287.
|
23. |
Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer, 2003, 3(10): 721-732.
|
24. |
Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol, 1999, 43 Suppl: S42-S51.
|
25. |
McLaughlin SH, Smith HW, Jackson SE. Stimulation of the weak ATPase activity of human hsp90 by a client protein. J Mol Biol, 2002, 315(4): 787-798.
|
26. |
经庆玲. MMP-2、MMP-9、VEGF 在人非小细胞肺癌中的表达及其与临床病理特征的相关性分析. 南宁: 广西医科大学, 2014.
|
27. |
王阿曼, 蔡欣, 周涛, 等. MMP-2、VEGF、CD105 和 Ki-67 在小细胞肺癌中的表达及预后相关性研究. 临床肿瘤学杂志, 2012, 17(11): 988-993.0.
|